Brain Disorder Research Moves Toward Clinical Testing

Research team moves closer to bringing new drug to market


Categories: Campus , Academic , Research

UM Regents Professor Richard Bridges
UM Regents Professor Richard Bridges

UM is one step closer to turning a discovery into a drug.

Promentis Pharmaceuticals, Inc., recently announced it will enter an exclusive agreement with UM to commercialize a discovery made by a team of UM faculty scientists that has the potential to treat brain cancer and possibly other disorders of the central nervous system.

The team, which is based in the Department of Biomedical and Pharmaceutical Sciences within UM’s Skaggs School of Pharmacy, includes professors Richard Bridges, Sarjubhai Patel, Nicholas Natale, Philippe Diaz, and Charles Thompson.

Their studies primarily focus on transporter proteins found on cells in the brain and spinal cord. Bridges likens transporters to turnstiles, controlling which small molecules get into and out of different cells. His team works to discover molecules that regulate activity of these transporters. In short, they seek to understand how alterations in transporters may contribute to central nervous system diseases and to develop drugs that will compensate for such changes.

The UM team’s patented research shows promise for treating various disorders of the brain. Equipped with expertise and resources not available at UM, Promentis Pharmaceuticals will advance the patented research to a clinical setting.

“Universities are great places for discovering innovations or breakthroughs that change our lives,” UM Director of Technology Transfer Joe Fanguy says. “We aren’t always equipped to transform those discoveries into real-world applications. In this case, UM has entered an exclusive agreement to take the research to the next level—developing novel drugs for the marketplace.”

This project represents one of several that have been initiated within UM’s Center for Structural & Functional Neuroscience and the Skaggs School of Pharmacy with support from the Montana Board of Research and Commercialization Technology. The goal of the CSFN/MBRCT is to facilitate the commercialization of research discoveries made on campus, particularly related to drugs and diagnostics for the treatment of neurodegenerative disorders and neurological diseases. 

“These projects provide a pathway to protect intellectual property, collaborate with companies, advance our discoveries into patient care, and have an economic impact in a way that we could never do by ourselves,” Bridges says. “The added value, of course, is that students are involved every step of the way.”

comments powered by Disqus